Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27614. Epub 2014 Jan 16.

2.

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.

Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L.

J Clin Invest. 2019 Jan 2;129(1):349-363. doi: 10.1172/JCI123391. Epub 2018 Dec 10.

3.

Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.

Aida K, Miyakawa R, Suzuki K, Narumi K, Udagawa T, Yamamoto Y, Chikaraishi T, Yoshida T, Aoki K.

Cancer Sci. 2014 Feb;105(2):159-67. doi: 10.1111/cas.12332. Epub 2014 Jan 4.

4.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

5.

Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.

Vijayakumar G, Palese P, Goff PH.

EBioMedicine. 2019 Nov;49:96-105. doi: 10.1016/j.ebiom.2019.10.032. Epub 2019 Oct 29.

6.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. Epub 2014 Jul 31.

7.

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Quezada SA, Peggs KS, Curran MA, Allison JP.

J Clin Invest. 2006 Jul;116(7):1935-45. Epub 2006 Jun 15.

8.

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.

Zhang J, Liu D, Li G, Staveley-O'Carroll KF, Graff JN, Li Z, Wu JD.

Sci Adv. 2017 May 17;3(5):e1602133. doi: 10.1126/sciadv.1602133. eCollection 2017 May.

9.

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.

Clin Cancer Res. 2010 May 15;16(10):2781-91. doi: 10.1158/1078-0432.CCR-09-3243. Epub 2010 May 11.

10.

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.

Iannone R, Miele L, Maiolino P, Pinto A, Morello S.

Am J Cancer Res. 2014 Mar 1;4(2):172-81. eCollection 2014.

11.

Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.

Son CH, Bae JH, Lee HR, Shin DY, Yang K, Park YS.

J Immunother. 2015 Apr;38(3):107-15. doi: 10.1097/CJI.0000000000000068.

PMID:
25751500
12.

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L.

Blood. 2008 Aug 15;112(4):1175-83. doi: 10.1182/blood-2007-11-125435. Epub 2008 Jun 3.

13.

Engineering Newcastle disease virus as oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines.

Vijayakumar G, McCroskery S, Palese P.

J Virol. 2019 Nov 6. pii: JVI.01677-19. doi: 10.1128/JVI.01677-19. [Epub ahead of print]

PMID:
31694938
14.

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ.

Cancer Res. 2009 Jan 15;69(2):609-15. doi: 10.1158/0008-5472.CAN-08-3529.

15.

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A.

Cancer Res. 2007 Jun 15;67(12):5929-39.

16.

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X.

J Transl Med. 2014 Feb 7;12:36. doi: 10.1186/1479-5876-12-36.

17.

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

Tang F, Du X, Liu M, Zheng P, Liu Y.

Cell Biosci. 2018 Apr 18;8:30. doi: 10.1186/s13578-018-0229-z. eCollection 2018.

18.

Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.

Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT.

J Transl Med. 2013 Jun 17;11:148. doi: 10.1186/1479-5876-11-148.

19.

Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity.

Li Y, Fang M, Zhang J, Wang J, Song Y, Shi J, Li W, Wu G, Ren J, Wang Z, Zou W, Wang L.

Oncoimmunology. 2015 Aug 12;5(2):e1074374. eCollection 2016 Feb.

20.

Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self.

Miska J, Bas E, Devarajan P, Chen Z.

Eur J Immunol. 2012 Oct;42(10):2584-96. doi: 10.1002/eji.201242590. Epub 2012 Aug 10.

Supplemental Content

Support Center